Notably, ASXL1 mutations were significantly associated with an increased cumulative incidence of BCR::ABL1 KD mutations during TKI therapy in adult CML patients, whereas this association was not observed in AYAs. Here, ASXL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.